H.C. Wainwright analyst Emily Bodnar says the departure of CEO Corinne Le Goff does not change Imunon’s timelines or guidance. The IMNN-001 Phase 2 topline data from the OVATION 2 study are still on track for the second half of 2024 for advanced newly diagnosed ovarian cancer and the company is on track to initiate the IMNN-101 Phase 1 study in Q2, the analyst tells investors in a research note. The firm believes Executive Chairman Michael, who was previously CEO, is well-equipped to continue operations until Imunon hires a new CEO. It keeps a Buy rating on the shares with a $12 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on IMNN:
- Imunon Announces CEO Resignation and Interim Leadership Transition
- IMUNON Announces Leadership Change
- Imunon announces lab confirms immunogenicity, protection with IMNN-101
- Independent Lab Confirms Immunogenicity and Protection with IMUNON’s IMNN-101 in a Live Virus Challenge Against SARS-CoV-2 Variant XBB.1.5
- Imunon announces Memorial Sloan Kettering Cancer center enrolling patients